Bayer Stock News

The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.

Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing ​site in New Albany, Ohio, part of a ‌push to boost the business's US revenue.

NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer's long-term growth strategy and commitment to innovation and patient ac...

Attorneys for ​three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately ‌test its Roundup weedkiller before selling it, starting a trial that could help determine the viability of some Roundup lawsuits after a US Supreme Court ruling in Bayer's favor this year.

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) in women receiving endocrine therapy for trea...

The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with ty...